The objective of this report was to perform a systematic review of the beneficial and harmful effects of migalastat 123 mg capsule (equivalent to 150 mg migalastat hydrochloride [HCl]) for long-term treatment of adults with a confirmed diagnosis of Fabry disease (FD) (deficiency of alpha-Gal A) and who have an alpha-galactosidase A (alpha-Gal A) mutation determined to be amenable by an in vitro assay.
Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.